Evidence map›Paper›PMID 41156673›Full record

SynthesisPathogens (Basel, Switzerland)2025

Resistance of

Matthew E Falagas, Laura T Romanos, Dimitrios Ragias, Charalampos Filippou

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ConsistentAntimicrobial agents and chemotherapy · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew E FalagasAlfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece.
Laura T RomanosAlfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece.
Dimitrios RagiasAlfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Greece.
Charalampos FilippouSchool of Medicine, European University Cyprus, 6 Diogenous Str., 2404 Nicosia, Cyprus.ORCID 0000-0002-9324-1641

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDue to the limited therapeutic options for patients with

methodsWe performed a thorough search of four databases for relevant studies. The Clinical and Laboratory Standards Institute (CLSI) sulbactam-durlobactam breakpoint for

resultsFrom 182 identified articles, 84 were thoroughly screened. Data extraction was performed on 20 articles (published 2017-2025) reporting on a total of 10,412 DISCUSSION: The low proportion of sulbactam-durlobactam resistance among

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsAzabicyclo CompoundsDrug Resistance, BacterialSulbactambeta-LactamasesHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesdurlobactamSulbactamA. baumanniiA. baumannii complexA. calcoaceticusA. nosocomialisA. pittiiETX2514hospital-acquired bacterial pneumoniapneumoniasulbactam–durlobactamventilator-associated bacterial pneumonia

Identifiers

PMID41156673
PMCPMC12566789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.